Literature DB >> 23344767

Echocardiography alone allows the determination of heart failure stages in rats with pressure overload.

Yasushige Shingu1, Paulo A Amorim, T Dung Nguyen, Moritz Osterholt, Michael Schwarzer, Torsten Doenst.   

Abstract

BACKGROUND: There is currently no standard for the assessment of contractile function in animals. We aimed to determine whether transthoracic echocardiography in rats with chronic pressure overload allows determining the stage of hypertrophy and heart failure (HF).
METHODS: Pressure overload was created by placement of a metal clip around the thoracic aorta at a weight of 40 to 50 g. After 1, 2, 6, 10, and 20 weeks, we performed echocardiography according to the American Heart Association guidelines (n = 26, four to six rats for each time point). We also obtained heart, lung, and body weights and regularly evaluated clinical signs of HF.
RESULTS: : Pressure overload caused significant hypertrophy within 1 week. Contractile function was normal until 6 weeks when diastolic dysfunction appeared. After 10 weeks of pressure overload, systolic function decreased. At 20 weeks, hearts were dilated and cardiac index was decreased. These findings correlated with increased lung-to-body weight ratio after 6 weeks and clinical signs of HF after 20 weeks.
CONCLUSION: Echocardiography alone allows the reproducible determination of HF stages after aortic constriction in rats. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2013        PMID: 23344767     DOI: 10.1055/s-0032-1326775

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  7 in total

1.  Mitochondrial reactive oxygen species production and respiratory complex activity in rats with pressure overload-induced heart failure.

Authors:  Michael Schwarzer; Moritz Osterholt; Anne Lunkenbein; Andrea Schrepper; Paulo Amorim; Torsten Doenst
Journal:  J Physiol       Date:  2014-06-20       Impact factor: 5.182

2.  GLP-1 Improves Diastolic Function and Survival in Heart Failure with Preserved Ejection Fraction.

Authors:  T Dung Nguyen; Yasushige Shingu; Paulo A Amorim; Christina Schenkl; Michael Schwarzer; Torsten Doenst
Journal:  J Cardiovasc Transl Res       Date:  2018-02-20       Impact factor: 4.132

3.  Neurotransmission to parasympathetic cardiac vagal neurons in the brain stem is altered with left ventricular hypertrophy-induced heart failure.

Authors:  Edmund Cauley; Xin Wang; Jhansi Dyavanapalli; Ke Sun; Kara Garrott; Sarah Kuzmiak-Glancy; Matthew W Kay; David Mendelowitz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-09-14       Impact factor: 4.733

Review 4.  Surgical and physiological challenges in the development of left and right heart failure in rat models.

Authors:  Michael G Katz; Anthony S Fargnoli; Sarah M Gubara; Elena Chepurko; Charles R Bridges; Roger J Hajjar
Journal:  Heart Fail Rev       Date:  2019-09       Impact factor: 4.214

5.  Increased Protein Tyrosine Phosphatase 1B (PTP1B) Activity and Cardiac Insulin Resistance Precede Mitochondrial and Contractile Dysfunction in Pressure-Overloaded Hearts.

Authors:  T Dung Nguyen; Michael Schwarzer; Andrea Schrepper; Paulo A Amorim; Daniel Blum; Claudia Hain; Gloria Faerber; Judith Haendeler; Joachim Altschmied; Torsten Doenst
Journal:  J Am Heart Assoc       Date:  2018-06-21       Impact factor: 5.501

6.  The IGF-1R Inhibitor NVP-AEW541 Causes Insulin-Independent and Reversible Cardiac Contractile Dysfunction.

Authors:  Christina Schenkl; Andrea Schrepper; Estelle Heyne; Torsten Doenst; Michael Schwarzer
Journal:  Biomedicines       Date:  2022-08-19

7.  A New Animal Model for Investigation of Mechanical Unloading in Hypertrophic and Failing Hearts: Combination of Transverse Aortic Constriction and Heterotopic Heart Transplantation.

Authors:  Andreas Schaefer; Yvonne Schneeberger; Justus Stenzig; Daniel Biermann; Marisa Jelinek; Hermann Reichenspurner; Thomas Eschenhagen; Heimo Ehmke; Alexander P Schwoerer
Journal:  PLoS One       Date:  2016-02-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.